Medtronic plc (MDT) Stock Analysis — April 2026 Rating, Price, and Forecast
Company Overview — What Does Medtronic plc Do?
Medtronic plc develops, manufactures, distributes, and sells device-based medical therapies to hospitals, physicians, clinicians, and patients worldwide. It operates through four segments: Cardiovascular Portfolio, Neuroscience Portfolio, Medical Surgical Portfolio, and Diabetes Operating Unit. The Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; AF ablation products; insertable cardiac monitor systems; mechanical circulatory support; TYRX products; and remote monitoring and patient-centered software. It also provides aortic valves; percutaneous coronary intervention stents, surgical valve replacement and repair products, endovascular stent grafts, percutaneous angioplasty balloons, and products to treat superficial venous diseases in the lower extremities. The Medical Surgical Portfolio segment offers surgical products, including surgical stapling devices, vessel sealing instruments, wound closure, electrosurgery products, surgical artificial intelligence and robotic-assisted surgery products, hernia mechanical devices, mesh implants, gynecology and lung products, and various therapies to treat diseases. The Neuroscience Portfolio segment offers products for spinal surgeons; neurosurgeons; neurologists; pain management specialists; anesthesiologists; orthopedic surgeons; urologists; urogynecologists; interventional radiologists; ear, nose, and throat specialists; and systems that incorporate energy surgical instruments. It also provides image-guided surgery and intra-operative imaging systems and robotic guidance systems used in robot assisted spine procedures; and therapies for vasculature in and around the brain. The Diabetes Operating Unit segment offers insulin pumps and consumables, and continuous glucose monitoring systems. The company was founded in 1949 and is headquartered in Dublin, Ireland. Medtronic plc (MDT) is classified as a large-cap stock in the Healthcare sector, specifically within the Medical Equipment industry. The company is led by CEO Geoffrey S. Martha and employs approximately 95,000 people. With a market capitalization of $110.5B, MDT is one of the prominent companies in the Healthcare sector.
Medtronic plc (MDT) Stock Rating — Reduce (April 2026)
As of April 2026, Medtronic plc receives a Reduce rating with a composite score of 46.2/100 and 2 out of 5 stars from the Blank Capital Research quantitative model.MDT ranks #2,349 out of 4,446 stocks in our coverage universe. Within the Healthcare sector, Medtronic plc ranks #283 of 838 stocks, placing it in the upper half of its Healthcare peers. The rating is generated by a multi-factor model that weighs quality (30%), momentum (25%), value (15%), investment (10%), stability (10%), and short interest (10%).
MDT Stock Price and 52-Week Range
Medtronic plc (MDT) currently trades at $87.10. The stock lost $0.81 (0.9%) in the most recent trading session. The 52-week high for MDT is $106.33, which means the stock is currently trading -18.1% from its annual peak. The 52-week low is $79.55, putting the stock 9.5% above its annual trough. Recent trading volume was 8.3M shares, reflecting moderate market activity.
Is MDT Overvalued or Undervalued? — Valuation Analysis
Medtronic plc (MDT) carries a value factor score of 45/100 in the Blank Capital model, indicating fair valuation relative to historical norms. The trailing price-to-earnings ratio is 22.15x, compared to the Healthcare sector average of 23.63x — a discount of 6%. The price-to-book ratio stands at 2.27x, versus the sector average of 2.75x. The price-to-sales ratio is 3.24x, compared to 1.66x for the average Healthcare stock. On an enterprise value basis, MDT trades at 17.41x EV/EBITDA, versus 6.34x for the sector.
Overall, MDT's valuation appears roughly in line with sector benchmarks, suggesting the market is pricing the stock fairly given its current fundamentals and growth trajectory. Neither deep value nor significantly overpriced, the stock occupies a middle ground on valuation.
Medtronic plc Profitability — ROE, Margins, and Quality Score
Medtronic plc (MDT) earns a quality factor score of 49/100, signaling below-average profitability metrics relative to the broader market. The return on equity (ROE) is 10.3%, compared to the Healthcare sector average of -43.5%, which is within a healthy range. Return on assets (ROA) comes in at 5.5% versus the sector average of -33.1%.
On a margin basis, Medtronic plc reports gross margins of 65.6%, compared to 71.5% for the sector. The operating margin is 18.6% (sector: -66.1%). Net profit margin stands at 14.6%, versus -58.7% for the average Healthcare stock. Revenue growth is running at 13.2% on a trailing basis, compared to 10.6% for the sector. Profitability is below benchmark levels, which may reflect industry headwinds, elevated reinvestment, or structural challenges.
MDT Debt, Balance Sheet, and Financial Health
Medtronic plc has a debt-to-equity ratio of 87.0%, compared to the Healthcare sector average of 32.0%. Leverage is within a manageable range for the industry, though investors should monitor debt trends over time. The current ratio is 2.42x, indicating strong short-term liquidity.
MDT has a beta of 0.60, meaning it is less volatile than the S&P 500, making it a relatively defensive holding. The stability factor score for Medtronic plc is 91/100, indicating low-volatility characteristics and consistent price behavior that appeals to risk-averse investors.
Medtronic plc Revenue and Earnings History — Quarterly Trend
In TTM 2026, Medtronic plc reported revenue of $34.23B and earnings per share (EPS) of $1.07. Net income for the quarter was $5.01B. Gross margin was 65.6%. Operating income came in at $6.37B.
In Q2 2026, Medtronic plc reported revenue of $8.96B and earnings per share (EPS) of $1.07. Net income for the quarter was $1.38B. Gross margin was 65.8%. Revenue grew 6.6% year-over-year compared to Q2 2025. Operating income came in at $1.69B.
In Q1 2026, Medtronic plc reported revenue of $8.58B and earnings per share (EPS) of $0.81. Net income for the quarter was $1.05B. Gross margin was 65.0%. Revenue grew 8.4% year-over-year compared to Q1 2025. Operating income came in at $1.45B.
In FY 2025, Medtronic plc reported revenue of $33.54B and earnings per share (EPS) of $3.63. Net income for the quarter was $4.69B. Gross margin was 65.3%. Revenue grew 3.6% year-over-year compared to FY 2024. Operating income came in at $5.96B.
Over the past 8 quarters, Medtronic plc has demonstrated a growth trajectory, with revenue expanding from $32.36B to $34.23B. Investors analyzing MDT stock should weigh these quarterly trends alongside the valuation and quality metrics discussed above.
MDT Dividend Yield and Income Analysis
Medtronic plc (MDT) currently pays a dividend yield of 3.0%. At this yield, a $10,000 investment in MDT stock would generate approximately $$301.00 in annual dividend income. The net margin of 14.6% provides reasonable coverage for the dividend, though investors should monitor payout sustainability.
MDT Momentum and Technical Analysis Profile
Medtronic plc (MDT) has a momentum factor score of 39/100, signaling weak relative price performance. Stocks with low momentum scores have historically tended to continue underperforming in the near term. The investment factor score is 28/100, which measures capital allocation efficiency and asset growth patterns. The short interest score of 32/100 signals elevated short interest, which can indicate bearish sentiment among institutional investors.
MDT vs Competitors — Healthcare Sector Ranking and Peer Comparison
Within the Healthcare sector, Medtronic plc (MDT) ranks #283 out of 838 stocks based on the Blank Capital composite score. This places MDT in the upper half of all Healthcare stocks in our coverage universe. Key competitors and sector peers include ASTRAZENECA PLC (AZN) with a score of 61.4/100, Sol-Gel Technologies Ltd. (SLGL) with a score of 56.6/100, VIEMED HEALTHCARE, INC. (VMD) with a score of 53.4/100, Innoviva, Inc. (INVA) with a score of 52.7/100, and JOHNSON & JOHNSON (JNJ) with a score of 51.7/100.
Comparing MDT against the S&P 500 benchmark is also instructive for understanding relative performance. Investors can view the full MDT vs S&P 500 (SPY) comparison to assess how Medtronic plc stacks up against the broader market across all factor dimensions.
MDT Next Earnings Date
No upcoming earnings date has been announced for Medtronic plc (MDT) at this time. Check the earnings calendar for the latest scheduling updates across all stocks in our coverage universe.
Should You Buy MDT? — Investment Thesis Summary
The quantitative profile for Medtronic plc suggests caution. Momentum is weak at 39/100, a headwind for near-term performance. Low volatility (stability score 91/100) reduces downside risk.
In summary, Medtronic plc (MDT) earns a Reduce rating with a composite score of 46.2/100 as of April 2026. The rating is derived from the Blank Capital Research methodology, which combines six factor dimensions into a single quantitative ranking. Investors should consider these quantitative signals alongside their own fundamental research, risk tolerance, and investment time horizon before making buy or sell decisions on MDT stock.
Related Resources for MDT Investors
Explore more research and tools: MDT vs S&P 500 comparison, top Healthcare stocks, stock screener, our methodology, quality factor explained, value factor explained, momentum factor explained. Compare MDT head-to-head with peers: MDT vs AZN, MDT vs SLGL, MDT vs VMD.